Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Army
Express Scripts
McKinsey
Harvard Business School
Farmers Insurance
McKesson
Boehringer Ingelheim
Deloitte
UBS

Generated: October 21, 2017

DrugPatentWatch Database Preview

Tris Pharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for TRIS PHARMA INC, and what generic alternatives to TRIS PHARMA INC drugs are available?

TRIS PHARMA INC has twenty-five approved drugs.

There are six US patents protecting TRIS PHARMA INC drugs.

There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and nineteen supplementary protection certificates in eight countries.

Summary for Applicant: Tris Pharma Inc

International Patents:19
US Patents:6
Tradenames:24
Ingredients:23
NDAs:25
Drug Master File Entries: (click here to view)5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
SOLUTION;ORAL091601-001Jul 23, 2010AARXNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
CLONIDINE
clonidine
TABLET, EXTENDED RELEASE;ORAL022500-002Dec 3, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tris Pharma Inc
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX
chlorpheniramine polistirex; hydrocodone polistirex
SUSPENSION, EXTENDED RELEASE;ORAL091632-001Oct 1, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
GABAPENTIN
gabapentin
SOLUTION;ORAL091286-001Mar 14, 2016AARXNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
cetirizine hydrochloride
SYRUP;ORAL090572-002Nov 16, 2012OTCNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tris Pharma Inc
DEXMETHYLPHENIDATE HYDROCHLORIDE
dexmethylphenidate hydrochloride
TABLET;ORAL207901-002Aug 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE
chlorpheniramine maleate; hydrocodone bitartrate
SOLUTION;ORAL206438-001Jan 27, 2015DISCNNoNo► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tris Pharma Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,198,864Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,202,537Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,491,935Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,790,700Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,549,989Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,337,890Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,675,704Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tris Pharma Inc Drugs

Country Document Number Estimated Expiration
Australia2007227569► Subscribe
Russian Federation2008140944► Subscribe
Spain2378573► Subscribe
Israel194042► Subscribe
Taiwan200812649► Subscribe
South Korea20080108520► Subscribe
European Patent Office2428205► Subscribe
China101400343► Subscribe
Austria536867► Subscribe
China102488652► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tris Pharma Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
2013 00059Denmark► SubscribePRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
C/GB12/028United Kingdom► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C/GB95/010United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
/2013Austria► SubscribePRODUCT NAME: KOMBINATION VON A) DEXTROMETHORPHAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE DEXTROMETHORPHANHYDROBROMID, UND INSBESONDERE DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT UND B) CHINIDIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE CHINIDINSULFAT, UND INSBESONDERE CHINIDINSULFATDIHYDRAT.; REGISTRATION NO/DATE: EU/1/13/833 20130626
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
2013 00059Denmark► SubscribePRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
C/GB08/020United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
QuintilesIMS
Merck
Cipla
Baxter
UBS
Express Scripts
McKesson
Chubb
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot